Big Pharma's increasing M&A enthusiasm; Manchin, Schumer reach deal on drug pricing; Earnings recaps; and more
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.
With Amber out on a well-deserved vacation this week, we’ve put this week’s report together. It’s been a fast-paced week, abuzz with a litany of Q2 earnings calls that provide an inside look into the workings of Big Pharma. Thanks for reading, have a great weekend, and see you next week. — Kyle LaHucik and Paul Schloesser
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.